PATRICK DEVAL L - 05 Jun 2024 Form 4 Insider Report for Cerevel Therapeutics Holdings, Inc.

Reporting relationship: Director
Issuer ticker: N/A
Reported as of: 05 Jun 2024
Net transaction value: $0
SEC form: 4
Accepted by SEC: 07 Jun 2024, 16:34:15 UTC
Prior SEC filing: 19 Mar 2024
Next SEC filing: 10 Jun 2024
Source filing: View source filing
Reporting owner signature: /s/ Mark Bodenrader, as Attorney-in-Fact

Key filing fact

PATRICK DEVAL L filed Form 4 for Cerevel Therapeutics Holdings, Inc. on 07 Jun 2024.

Key facts

This page summarizes PATRICK DEVAL L's Form 4 filing for Cerevel Therapeutics Holdings, Inc..
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 07 Jun 2024, 16:34.

Change

Previous filing in this sequence was filed on 19 Mar 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CERE transaction

Common Stock

Award

Transaction value
Shares: +10,461
Change %: +319%
Price
Shares after: 13,743
Date: 05 Jun 2024
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The shares reported in this transaction represent Restricted Stock Units ("RSUs") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. 100% of the RSUs subject to this grant shall vest upon the earlier of: (i) the one-year anniversary of the Grant Date, or (ii) the 2025 annual meeting of stockholders of the Company.